title: Reforming pharmaceutical industry-physician financial relationships: lessons from the United States, France, and Japan.
abstract: This article compares the means that the United States, France, and Japan use to oversee pharmaceutical industry-physician financial relationships. These countries rely on professional and/or industry ethical codes, anti-kickback laws, and fair trade practice laws. They restrict kickbacks the most strictly, allow wide latitude on gifts, and generally permit drug firms to fund professional activities and associations. Consequently, to avoid legal liability, drug firms often replace kickbacks with gifts and grants. The paper concludes by proposing reforms that address problems that persist when firms replace kickbacks with gifts and grants based on the experience of the three countries.
authors.affiliation: Harvard University, USA.
authors.forename: Marc A
authors.initials: MA
authors.lastname: Rodwin
mesh_terms: D032781:Codes of Ethics; D016265:Conflict of Interest; D004345:Drug Industry / Q000941:ethics*; D004502:Education, Medical, Continuing / Q000191:economics; D005602:France; D005607:Fraud / Q000941:ethics / Q000331:legislation & jurisprudence; D037921:Gift Giving / Q000941:ethics; D006801:Humans; D007400:Interprofessional Relations / Q000941:ethics*; D007564:Japan; D010820:Physicians / Q000941:ethics*; D010818:Practice Patterns, Physicians'; D014146:Training Support / Q000331:legislation & jurisprudence; D014481:United States